colorectal cancer treatments Kansas City

Cirrhosis NASH Trials

Age – Adult (18-85)
Gender – Female, Male

Disease Type – Cirrhosis Hepatic Encephalopathy

Phase – 3
Length -72 weeks
Compensation available.
Inclusion:
– Cirrhosis with Hepatic Encephalopathy
– Medically controlled ascites or no ascites present
– West Haven Criteria <2
– Males and non-pregnant females
Exclusion:
– Allergy to Rifaximin, rifampin, rifamycin antimicrobial agent
– Receiving dialysis
– Active Cancer diagnosis

Salix RNLC3131: A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.

 

Age – Adult (18-85)
Gender – Female, Male

Disease Type – Cirrhosis Hepatic Encephalopathy

Phase – 3
Length -72 weeks
Compensation available.
Inclusion:
– Cirrhosis Medically controlled ascites
– West Haven Criteria <2
– Males and non-pregnant females
Exclusion:
– Allergy to Rifaximin, rifampin, rifamycin antimicrobial agent
– Receiving dialysis

– Active Cancer diagnosis

MGL-3196-19: A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES)

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) – Full Text View – ClinicalTrials.gov

Learn More

Additional Information

For more information on what current clinical trials are available at Kansas City Research Institute or additional information and how to get involved, please contact our office phone at (816)759-2574 or send by email at study@kcresearchinstitute.com.

Contact Us